Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dipender Gill

Showing results (301-310 of 325) with videos related to

Pageof 33
Sort By:
British Journal of Cancer|November 23, 2024
Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation studyWing Ching Chan, Lili Liu, Emmanouil Bouras, et al.
American Journal of Human Genetics|August 8, 2025
Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunctionHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
Medrxiv : the Preprint Server for Health Sciences|March 4, 2025
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
BMJ Medicine|March 20, 2023
The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation studyVille Karhunen, Dipender Gill, Jian Huang, et al.
Diabetologia|May 12, 2023
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysisJames Yarmolinsky, Emmanouil Bouras, Andrei Constantinescu, et al.
Circulation. Heart Failure|February 1, 2024
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection FractionJoe David Azzo, Marie-Joe Dib, Loukas Zagkos, et al.
International Journal of Epidemiology|May 10, 2024
Identification of potential mediators of the relationship between body mass index and colorectal cancer: a Mendelian randomization analysisEmmanouil Bouras, Dipender Gill, Verena Zuber, et al.
JACC. Basic to Translational Science|November 13, 2024
Proteome-Wide Genetic Investigation of Large Artery StiffnessMarie-Joe Dib, Joe David Azzo, Lei Zhao, et al.
Journal of the American Heart Association|February 29, 2024
Proteomic Associations of Adverse Outcomes in Human Heart FailureMarie-Joe Dib, Michael G Levin, Lei Zhao, et al.
Royal Society Open Science|January 4, 2021
ACE inhibition and cardiometabolic risk factors, lung <i>ACE2</i> and <i>TMPRSS2</i> gene expression, and plasma ACE2 levels: a Mendelian randomization studyDipender Gill, Marios Arvanitis, Paul Carter, et al.
Pageof 33

Showing results (301-310 of 325) with videos related to

Sort By:
Pageof 33
British Journal of Cancer|November 23, 2024
Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation studyWing Ching Chan, Lili Liu, Emmanouil Bouras, et al.
American Journal of Human Genetics|August 8, 2025
Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunctionHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
Medrxiv : the Preprint Server for Health Sciences|March 4, 2025
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
BMJ Medicine|March 20, 2023
The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation studyVille Karhunen, Dipender Gill, Jian Huang, et al.
Diabetologia|May 12, 2023
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysisJames Yarmolinsky, Emmanouil Bouras, Andrei Constantinescu, et al.
Circulation. Heart Failure|February 1, 2024
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection FractionJoe David Azzo, Marie-Joe Dib, Loukas Zagkos, et al.
International Journal of Epidemiology|May 10, 2024
Identification of potential mediators of the relationship between body mass index and colorectal cancer: a Mendelian randomization analysisEmmanouil Bouras, Dipender Gill, Verena Zuber, et al.
JACC. Basic to Translational Science|November 13, 2024
Proteome-Wide Genetic Investigation of Large Artery StiffnessMarie-Joe Dib, Joe David Azzo, Lei Zhao, et al.
Journal of the American Heart Association|February 29, 2024
Proteomic Associations of Adverse Outcomes in Human Heart FailureMarie-Joe Dib, Michael G Levin, Lei Zhao, et al.
Royal Society Open Science|January 4, 2021
ACE inhibition and cardiometabolic risk factors, lung <i>ACE2</i> and <i>TMPRSS2</i> gene expression, and plasma ACE2 levels: a Mendelian randomization studyDipender Gill, Marios Arvanitis, Paul Carter, et al.
Pageof 33